TB Alliance

FDA approves pretomanid for highly drug-resistant forms of TB

Pretomanid receives FDA approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB.

Read More →

TB community urges global leaders to “Walk the Talk” on investing in TB research

On July 28th in South Africa, more than 100 members of the TB research community marched under the Louder than TB banner in the Walk the Talk event to raise awareness for TB and TB research.

Read More →

New milestone for children with TB reached as one million treatments of child-friendly medicines are ordered

SYDNEY (June 18, 2019)—TB Alliance today announced that one million treatment courses of child-friendly tuberculosis (TB) medicines have been ordered by 93 countries in the three years since introduction of the products.1 The new medicines, which were first introduced nationally in Kenya in September 2016, are easier for caregivers to administer and for children to take. The announcement took place at the first International Global Health Security Conference in Sydney.

Read More →

FDA Antimicrobial Drugs Advisory Committee recommends approval of pretomanid

Investigational drug pretomanid is under regulatory review by FDA for treatment of XDR-TB and treatment-intolerant or non-responsive MDR-TB as part of a new investigational regimen.

Read More →

TB, among the oldest infectious diseases, is now the world’s deadliest – It’s Time to invest in solutions

GENEVA  (May 22, 2019) - This week at the Seventy-second World Health Assembly, TB Alliance is joining our partners in global health and product development to urge increased global funding and action to eradicate tuberculosis (TB). Today, delegates are assessing progress made since last year’s UN High Level Meeting (HLM) on TB as well as the 2017 HLM on Antimicrobial Resistance (AMR).

Read More →

TB Alliance and partners form multidisciplinary center for translational TB drug research

NEW YORK, NY (May 9, 2019)—The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a Center of Excellence in Translational Research (CETR) grant (U19AI142735) for tuberculosis (TB) drug development. New translational research to develop novel anti-TB medicines is being carried out with partners at the University of Illinois at Chicago, Harvard University, Johns Hopkins University, and Research Triangle Institute.

Read More →

TB Alliance and Mylan announce global collaboration to commercialize investigational drug pretomanid as part of two regimens to treat TB

NEW YORK, HERTFORDSHIRE, England and PITTSBURGH – April 18, 2019 – Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V. (NASDAQ: MYL), today announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).

Read More →

TB medicine pretomanid enters regulatory review process in the United States

NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has been accepted for review by the United States Food and Drug Administration (FDA). The application is for the use of pretomanid as part of a new regimen, in combination with bedaquiline and linezolid, for the treatment of extensively drug-resistant (XDR) TB, treatment intolerant multidrug-resistant (MDR) TB, and treatment non-responsive MDR-TB.

Read More →

Schrödinger and TB Alliance announce collaboration to accelerate TB drug discovery

Partnership merges Schrödinger’s advanced modeling capabilities with TB Alliance’s expertise in tuberculosis biology to accelerate the development of next-generation treatments

Read More →

TB Alliance receives GHTC Partnership Award for development of child-friendly TB medicines

[November 28, 2018, WASHINGTON, D.C.] – TB Alliance and partners were honored today as the winner of the Global Health Technologies Coalition (GHTC) 2018 Innovating for Impact Partnership Award, for the development of improved child-friendly tuberculosis (TB) medicines. Since the improved medicines were introduced in 2016, 85 countries have procured more than 800,000 treatment courses. Appropriately-dosed and palatable, these new medicines are improving TB treatment and survival for the estimated one million children stricken with TB each year.

Read More →

Page 1 of 7 · Total posts: 10

1 2 Last→